Nexstar Media reported a 77% revenue increase to $2.1 billion in Q3, driven by its TEGNA acquisition and high political ad spending. Legal delays have postponed $225 million in expected synergies from the TEGNA deal, but Nexstar's strong free cash flow is helping reduce debt quickly and maintain its 3.7% dividend. The company’s standalone value is estimated at $225 per share, with potential upside to $300 if TEGNA integration and synergies proceed as planned. Despite legal challenges, Nexstar remains a buy due to its solid financial performance and growth prospects.
Nexstar Media's Q3 revenue surged 77% to $2.1 billion, boosted by its TEGNA acquisition and political ad spending. For readers following the US media sector, here is Pluang's market snapshot as of Nov 10, 2026 22:23 WIB: Among 57 priced media stocks, 16 rose and 40 fell. Notable movers include EchoStar Corporation (ECHO) at USD 104.35 with a 3.12% gain and a typical hold time of 12 days, Sirius XM Holdings Inc (SIRI) at USD 31.84 with a 2.56% loss but 100% buy order activity, and Liberty Global Ltd Class C (LBTYK) at USD 9.97 with a 2.52% gain and a typical hold time of 22 days.
As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its sta...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...
Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...
Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...
